These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12201079)

  • 21. Insulin nanoparticles: stability and aerosolization from pressurized metered dose inhalers.
    Nyambura BK; Kellaway IW; Taylor KM
    Int J Pharm; 2009 Jun; 375(1-2):114-22. PubMed ID: 19481697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of initial atomized droplet size on residual particle size from pressurized metered dose inhalers.
    Sheth P; Stein SW; Myrdal PB
    Int J Pharm; 2013 Oct; 455(1-2):57-65. PubMed ID: 23911912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Issues surrounding MDI formulation development with non-CFC propellants.
    Kontny MJ; Destefano G; Jager PD; McNamara DP; Turi JS; Van Campen L
    J Aerosol Med; 1991; 4(3):181-7. PubMed ID: 10147677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humidity affects the morphology of particles emitted from beclomethasone dipropionate pressurized metered dose inhalers.
    Ivey JW; Bhambri P; Church TK; Lewis DA; McDermott MT; Elbayomy S; Finlay WH; Vehring R
    Int J Pharm; 2017 Mar; 520(1-2):207-215. PubMed ID: 28167262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times.
    Leach CL; Colice GL
    J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23(6):355-61. PubMed ID: 20575669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclometasone dipropionate (BDP Modulite).
    Bousquet J; Cantini L
    Respir Med; 2002 Aug; 96 Suppl D():S17-27. PubMed ID: 12201078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers.
    Buttini F; Miozzi M; Balducci AG; Royall PG; Brambilla G; Colombo P; Bettini R; Forbes B
    Int J Pharm; 2014 Apr; 465(1-2):42-51. PubMed ID: 24491530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A correlation equation for the mass median aerodynamic diameter of the aerosol emitted by solution metered dose inhalers.
    Ivey JW; Lewis D; Church T; Finlay WH; Vehring R
    Int J Pharm; 2014 Apr; 465(1-2):18-24. PubMed ID: 24524827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Particle size study of nine metered dose inhalers, and their deposition probabilities in the airways.
    Bouchikhi A; Becquemin MH; Bignon J; Roy M; Teillac A
    Eur Respir J; 1988 Jun; 1(6):547-52. PubMed ID: 3169224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone.
    Leach CL; Davidson PJ; Boudreau RJ
    Eur Respir J; 1998 Dec; 12(6):1346-53. PubMed ID: 9877489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pressurized metered dose inhalers: chlorofluorocarbon to hydrofluoroalkane transition-valve performance.
    Cummings RH
    J Allergy Clin Immunol; 1999 Dec; 104(6):S230-6. PubMed ID: 10588980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of formulation and spacer device on the in vitro performance of solution chlorofluorocarbon-free propellant-driven metered dose inhalers.
    Smyth HD; Beck VP; Williams D; Hickey AJ
    AAPS PharmSciTech; 2004 Feb; 5(1):E7. PubMed ID: 15198528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers.
    Zhu B; Traini D; Chan HK; Young PM
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1625-37. PubMed ID: 24087854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction. Modulite: simplifying the changeover.
    Bousquet J
    Respir Med; 2002 Aug; 96 Suppl D():S1-2. PubMed ID: 12201077
    [No Abstract]   [Full Text] [Related]  

  • 35. Influence of propellant composition on drug delivery from a pressurized metered-dose inhaler.
    Williams RO; Repka M; Liu J
    Drug Dev Ind Pharm; 1998 Aug; 24(8):763-70. PubMed ID: 9876524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Propellant-driven metered-dose inhalers for pulmonary drug delivery.
    Smyth HD
    Expert Opin Drug Deliv; 2005 Jan; 2(1):53-74. PubMed ID: 16296735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydrofluoroalkane mandate in effect January 1, 2009: Switch from chlorofluorocarbon- to hydrofluoroalkane-propelled inhalers requires active transition.
    Peters S
    Clin Cornerstone; 2009; 9(3):50-3. PubMed ID: 19781516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moisture uptake and its influence on pressurized metered-dose inhalers.
    Williams RO; Hu C
    Pharm Dev Technol; 2000; 5(2):153-62. PubMed ID: 10810745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pressurized metered dose inhaler (pMDI) remains the most commonly prescribed device for the delivery of inhaled asthma medications.
    Braunstein G; Sharma R
    Respir Med; 2000 Jun; 94 Suppl B():S1-2. PubMed ID: 10919678
    [No Abstract]   [Full Text] [Related]  

  • 40. The change to non-CFC metered dose inhalers.
    Rubinfeld A
    Aust Fam Physician; 1997 Dec; 26(12):1412-4. PubMed ID: 9470296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.